VIS achieved the important milestone of obtaining hit compounds through joint drug discovery research with Toray. Although this indicated progress in the joint research, no milestone income or other payments will arise, and there was a period of buying for a reassessment immediately after the announcement.
Veritas In Silico (VIS) has been advancing the development of small-molecule drugs targeting messenger RNA through joint drug discovery research with Toray. The latest announcement reported that it had achieved the milestone of obtaining hit compounds, an important stage in the research.
It was also explained that achieving this milestone would not result in any milestone income or other payments. No direct financial impact was indicated, but progress in the joint research attracted market attention.
The announcement also stated that the contract was signed in July 2021. In connection with this, there were periods when the issuance of stock acquisition rights affected the share price, but the achievement of the milestone prompted moves to reassess the shares.